« Back to report listing

OVERVIEW

Cost:$2500

PUBLICATION DATE:October 2010

THERAPEUTIC CLASS:METABOLIC DISORDERS

Number of Pages:84

standard report icon

US Type 2 Diabetes

Market Forecast & Pipeline Analysis 2010-2013

REPORT SUMMARY

PharmaPeek's US Type 2 Diabetes Market Report provides valuable insight and access to the competitive information necessary to make decisions regarding the direction of the market from 2010-2013. Our report features analyzed information gathered from pharmaceutical, payer, and key opinion leader interviews. This report reveals what changes lay ahead for the diabetes market in the US, and evaluates current drugs along with projections on drugs poised to influence the future market.


EXECUTIVE SUMMARY

Diabetes is one of the most common diseases in the United States, affecting more than 24 million people. It is a metabolic disorder mainly caused by a defect in insulin production or absorption, resulting in a high level of blood glucose or blood sugar. A person having blood glucose level HbA1c of greater than seven is considered to be diabetic. It is estimated that approximately 90 to 95 percent of diabetics are type 2 diabetics and can be treated by oral anti-diabetics or with a combination of injectable insulin and anti-diabetic drugs.

In 2008, the US anti-diabetic market was estimated to be worth $11.5 billion. The market is forecasted to grow at a cumulative annual growth rate (CAGR) of 6.4 percent over the forecast period. By the end of the forecast period, 2013, the market is estimated to generate $15.7 billion in revenues.

Our PharmaPeek diabetes report provides detailed analyses into the potential growth in revenue from the new DPP-IVs and GLP-1s. The report also delivers information on which segments are poised to grow the most over our forecast period as some of the biggest selling drugs lose patent protection. We provide exclusive payer opinions on how effective the current anti-diabetic armamentarium is and what managed care sees as keys to the future.

PharmaPeek utilizes our deep expertise in the field of diabetes to provide an accurate and detailed SWOT analysis of some of the most promising agents about to come to market, such as liraglutide, exenatide LAR, saxagliptin, dapagliflozin, and many more.

PharmaPeek also provides detailed pipeline analysis about which companies are developing the most anti-diabetics and where they are in development. Our report breaks down the therapeutic area as a whole, in order to show readers which companies are the most heavily invested. PharmaPeek also provides an up-to the minute picture of both early and late phase drugs.


TABLE OF CONTENTS

  • Chapter 1: Introduction to Diabetes
    • Types of Diabetes
  • Chapter 2: Epidemiology
  • Chapter 3: Diabetes Treatment
    • Insulin
    • Oral Anti-diabetics
    • Injectable Drugs
  • Chapter 4: The Type 2 Diabetes Market Analysis
    • Key Drivers for the Type 2 Diabetes Market
    • Key Restraints for the Type 2 Diabetes Market
    • Major Challenges for the Type 2 Diabetes Market
    • Regulations Impacting the Growth and Development of T2D Market
    • Overview of the Insulin Market in the United States
    • Overview of the Oral and Non-Insulin Injectable Anti-diabetic Market in the United States
  • Chapter 5: Type 2 Diabetes Market Analysis
    • Type 2 Diabetes Market Analysis
  • Chapter 6: Marketing and Sales Structure
    • Selling Message
    • Off Label Use
    • Key Customer Group for Anti-diabetics
    • Sales Force Analysis
  • Chapter 7: Pipeline Analysis
    • DPP-4
    • GLP-1 analogs
    • TZDs
    • Type 2 Diabetes Market Analysis: By Development Phase
    • Type 2 Diabetes Pipeline Analysis: By Class, 2009
  • Chapter 8: Late Phase Analysis
  • Chapter 9: Type 2 Diabetes Market: Upcoming Technologies
  • Chapter 10: Type 2 Diabetes: A Managed Care Perspective
    • Formulary Tiers
    • Managed Care Perspective
    • Current and Future Diabetes Management Approach

COMPANIES DISCUSSED

  • Pfizer
  • Novo Nordisk
  • Bristol-Myer Squibb
  • Eli Lilly
  • sanofi-aventis
  • Ranbaxy
  • Parke-Davis
  • GSK
  • Takeda
  • Bayer
  • Merck
  • Amylin
  • Nektar Therapeutics
  • Aradigm
  • MannKind
  • Alkermes
  • Biocon
  • Emisphere Technologies
  • Generex Biotechnology
  • Coremed
  • Biodel
  • Oramed
  • MDRNA
  • Diasome
  • CPEX
  • MicroDose
  • Dermisonics
  • Altea
  • Daiichi Sankyo
  • Dr. Reddy's
  • Metabloic Solutions Development
  • Perlegen Sciences
  • Novartis
  • AstraZeneca
  • Boeringher Ingelheim
  • Forest Laboratories
  • Roche
  • ConjuChem
  • Ispen
  • Isis
  • OSI
  • Elixir
  • Vivus
  • Incyte
  • N-Gene
  • CombinatoRx
  • Metabolex
  • Oramed
  • Johnson and Johnson
  • Xoma

DRUGS DISCUSSED

  • Avandia
  • Januvia
  • Humulin
  • Novolog
  • Humalog
  • Amaryl
  • Diabenese
  • Prandin
  • Starlix
  • Fortamet
  • Glumetza
  • Riomet
  • Glucophage
  • Rezulin
  • Avandaryl
  • Avandamet
  • ACTOS
  • ACTOplus met
  • ACTOplus met XR
  • Precose
  • Glyset
  • Sitagliptin
  • Byetta
  • Symlin
  • Exenatide
  • Byetta LAR
  • Victoza
  • alogliptin
  • Onglyza
  • Lantus
  • Levemir
  • Apidra
  • Exubera
  • AERx
  • AIR Insulin System
  • AFRESA
  • IN-105
  • Oral formulation
  • Oral-lyn
  • Alveair
  • APIDRA SoloSTAR
  • NovoMix 50 and 70
  • VIAiect
  • N5401
  • ORMD-0801
  • NA
  • HDV1
  • HDV-B
  • Oral HDV-1
  • Ora-lyn
  • Nasulin
  • VIAtab
  • ODose
  • UStrip
  • Intesulin
  • Alevair
  • AT1391
  • Glocotrol
  • Glocotrol XL
  • Micronase
  • Glynase
  • Diovan
  • Glinsuna
  • Metgluna
  • Obimet
  • Dianben
  • Diabex
  • Diaformin
  • AvandametXR
  • Rivoglitazone
  • Balaglitazone
  • Mitaglitazone
  • Netoglitazone
  • Janumet
  • Galvus
  • Eucreas
  • Aloglitptin
  • Ondero
  • Phenomix
  • R1579
  • SYR-472
  • TAK-100
  • Liraglutide
  • Exenatide LAR
  • PC-DAC
  • Taspoglutide
  • Syncria
  • Lixisenatide
  • NN9535
  • GLP-1 FC
  • GLP-1 PEG
  • Oral GLP-1
  • Intranasal exenatide
  • Transdermal exenatide
  • Inhaled GLP-1
  • Saxagliptin
  • Linagliptin
  • Dutogliptin
  • Dapagliflozin
  • Welchol
  • Novolin R
  • Novolin N
  • PrandiMet
  • Diabeta
  • Glimepiride
  • Alogliptin
  • Canagliflozin
  • Remogliflozin
  • Acarbose
  • Chloopropamide
  • Glimepiride
  • Metformin XR